IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1124.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 22-Jun-2012
Brain Disorders & Therapy
GMCSF treatment associated with improved cognition in cancer patients
Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.
American Cancer Society, Byrd Alzheimer's Institute

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3303
University of South Florida (USF Health)

Public Release: 22-Jun-2012
Grb2 holds powerful molecular signaling pathway in check
Once considered merely a passive link between proteins that matter, Grb2 - pronounced "grab2" - actually lives up to its nickname with its controlling grip on an important cell signaling pathway, scientists at the University of Texas MD Anderson Cancer Center report in the June 22 issue of Cell.

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 21-Jun-2012
Brain
Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Multiple sclerosis patients appear to have a lower cancer risk, according to a new study led by researchers at the University of British Columbia and Vancouver Coastal Health.
Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Michael Smith Foundation for Health Research

Contact: Melissa Ashman
mashman@brain.ubc.ca
604-827-3396
University of British Columbia

Public Release: 21-Jun-2012
Molecular Cell
Enzyme offers new therapeutic target for cancer drugs
Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs.
National Institutes of Health, Ruth L. Kirchstein National Research Service Award, Howard Hughes Medical Institute

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 21-Jun-2012
Chemistry and Biology
New candidate drug stops cancer cells, regenerates nerve cells
Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites. Researchers from Cincinnati Children's Hospital Medical Center report their findings online June 21 in Chemistry & Biology. The scientists named their lead drug candidate "Rhosin" and hope future testing shows it to be promising for the treatment of various cancers or nervous system damage.
National Institutes of Health

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center

Public Release: 21-Jun-2012
Nature Reviews Cancer
Moffitt researchers: Darwin's principles say cancer will always evolve to resist treatment
According to researchers at Moffitt Cancer Center, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection. Natural selection was the process identified by Darwin by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better "fit" the organism to the environment.
NIH/National Cancer Institute

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 21-Jun-2012
Chemistry & Biology
New anti-inflammatory drugs pinch off reactive oxygen species at the source
Scientists have identified a new type of anti-inflammatory compound that may be useful in treating a wide range of conditions, including neurodegenerative and autoimmune diseases. These compounds inhibit the enzyme Nox2, part of a family of enzymes responsible for producing reactive oxygen species.
NIH/National Cancer Institute, National Institutes of Health, NIH/National Institute of Mental Health

Contact: Quinn Eastman
404-727-7829
Emory University

Public Release: 21-Jun-2012
Genes & Development
Notre Dame researcher's paper examines the biology of tumor-derived microvesicles
A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients.

Contact: Crislyn-D'Souza-Schorey
cdsouzas@nd.edu
574-631-3735
University of Notre Dame

Public Release: 21-Jun-2012
Journal of Thoracic and Cardiovascular Surgery
Task force recommends new lung cancer screening guidelines
A lung screening and surveillance task force, established by the American Association for Thoracic Surgery and led by medical professionals from Brigham and Women's Hospital, is strongly recommending new guidelines for lung cancer screening. The guidelines were published this week in the online edition of the Journal of Thoracic and Cardiovascular Surgery.
American Association for Thoracic Surgery

Contact: Tom Langford
tlangford@partners.org
617-534-1605
Brigham and Women's Hospital

Public Release: 21-Jun-2012
Proceedings of the National Academy of Sciences
Cancers with disorganized 'traffic systems' more difficult to treat: U of A research
Medical researchers at the University of Alberta reviewed test results from thousands of patients with various types of cancer and discovered that "disorganized" cancers were more difficult to treat and consistently resulted in lower survival rates.
Alberta Cancer Foundation

Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry

Public Release: 21-Jun-2012
2012 International Conference on Zebrafish Development and Genetics
Versatility of zebrafish research highlighted at international conference
Amazingly, the small, black-and-white striped zebrafish has biological similarities to humans, and is increasingly a popular model organism for studying vertebrate development, genetics, physiology, and mechanisms of disease as featured at the ongoing 2012 International Zebrafish Development and Genetics Conference in Madison, Wisc.

Contact: Phyllis Edelman
pedelman@genetics-gsa.org
301-351-0896
Genetics Society of America

Public Release: 21-Jun-2012
Blood
Stopping and starting cancer cell cycle weakens and defeats multiple myeloma
Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.
NIH/National Cancer Institute, Leukemia and Lymphoma Society, Starr Cancer Consortium

Contact: Lauren Woods
law2014@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

Public Release: 20-Jun-2012
Neuron
Proposed drug may reverse Huntington's disease symptoms
With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models.
CHDI Foundation

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 20-Jun-2012
Nature
Gene sequencing project identifies potential drug targets in common childhood brain tumor
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
National Institutes of Health, Pediatric Cancer Genome Project, Collaborative Ependymoma Research Network, Musicians against Childhood Cancer, Noyes Brain Tumour Foundation, ALSAC

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital

Public Release: 20-Jun-2012
Nature
Breast cancer's many drivers
Breast cancer is not a single disease, but a collection of diseases with dozens of different mutations that crop up with varying frequency across different breast cancer subtypes. In one of the largest breast cancer sequencing efforts to date, scientists from the Broad Institute, the National Institute of Genomic Medicine in Mexico City, Beth Israel Deaconess Medical Center, and Dana-Farber Cancer Institute have discovered surprising alterations in genes not previously associated with breast cancer.
NIH/National Cancer Institute, National Institutes of Health, Carlos Slim Health Institute

Contact: Nicole Davis
ndavis@broadinstitute.org
617-714-7152
Broad Institute of MIT and Harvard

Public Release: 20-Jun-2012
American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges
Novel chemotherapy agent appears to be a promising pancreatic cancer treatment
A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising future treatment for pancreatic ductal adenocarcinoma, according to preclinical results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held June 18-21.

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 20-Jun-2012
Journal of the Royal Society of Medicine
Controversial vaccine trial should never have been run in India, researchers say
Research published today in the Journal of the Royal Society of Medicine raises further questions about a trial of HPV vaccines in India.

Contact: Kerry Noble
k.noble@qmul.ac.uk
44-020-788-27943
Queen Mary, University of London

Public Release: 20-Jun-2012
American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges
High-fat/calorie diet accelerates development of pancreatic cancer
Study results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held June 18-21, strongly suggest that a diet high in fat and calories can hasten the development of pancreatic cancer in humans.

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 20-Jun-2012
Gynecologic Oncology
Misidentified and contaminated cell lines lead to faulty cancer science
A University of Colorado Cancer Center study published this week in the journal Gynecologic Oncology shows that due to a high rate of contamination, misidentification and redundancy in widely available cell lines, researchers may be drawing faulty conclusions.
NIH/National Cancer Institute

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 20-Jun-2012
British Journal of Urology International
New drugs, new ways to target androgens in prostate cancer therapy
Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 20-Jun-2012
Molecular Nutrition and Food Research
Study links carcinogens to cancer stem cells -- but spinach can help
Researchers for the first time have traced the actions of a known carcinogen in cooked meat to its complex biological effects on microRNA and cancer stem cells. They also found that spinach can help prevent some of the damage done by this carcinogen.
National Institutes of Health

Contact: Rod Dashwood
rod.dashwood@oregonstate.edu
541-737-8101
Oregon State University

Public Release: 20-Jun-2012
Clinical Cancer Research
UW research shows new prognosis tool for deadly brain cancer
A diagnosis of glioblastoma multiforme (GBM) is generally a death sentence, but new research from the University of Wisconsin-Madison lab of Dr. John Kuo shows that at least one subtype is associated with a longer life expectancy. This discovery could help with better patient prognoses and lead to targeted drug treatments for GBM subtypes.
NIH/National Cancer Institute, Wisconsin Partnership Program, Center for Stem Cell and Regenerative Medicine, University of Wisconsin-Madison

Contact: Susan Lampert Smith
ssmith5@uwhealth.org
608-262-7335
University of Wisconsin-Madison

Public Release: 20-Jun-2012
Journal of Cell Science
Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
A molecule widely believed to fight many forms of cancer actually helps deadly thyroid tumors grow, and cancer therapies now being tested in humans might boost the activity of this newly revealed bad guy, researchers at Mayo Clinic in Florida say.

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic

Public Release: 20-Jun-2012
Husband-wife team set out to improve breast cancer exams
Cancer survivors and researchers Lorraine Olson and Robert Throne are working to change the way cancer is diagnosed. Together, this husband-wife team use TACC's supercomputing resources to create mathematical models to improve early detection efforts. This research could be instrumental in the development of a new robotic device that will mimic manual breast exams.

Contact: Faith Singer-Villalobos
faith@tacc.utexas.edu
512-232-5771
University of Texas at Austin, Texas Advanced Computing Center

Public Release: 20-Jun-2012
Naunyn-Schmiedeberg's Archives of Pharmacology
Double the pain: RUB biologists find the cause of pain in the treatment of fair skin cancer
Apply the ointment, light on, light off – that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy. Why the treatment with ointment and red light can be so painful has now been uncovered by researchers from the RUB. They identified the ion channels involved and signaling molecules secreted by the cancer cells.

Contact: Dr. Ben Novak
Ben.Novak@rub.de
49-234-322-4331
Ruhr-University Bochum

Showing releases 1001-1025 out of 1124.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases

     

 

 

EurekAlert!